Evidence map›Paper›PMID 42218200›Full record

ArticleScientific data2026

Quantitative transcriptome and proteome maps of classical nonclinical species.

Elias Oziolor, Liang Xue, Dennis Pelletier, Darien Capunitan, Emi Kimoto, Joel D Federspiel, Mark Sheehan, Seda Arat, Leah Newman, Gahyun Lee and 5 more

Abstract readDataset
In one paragraph

Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elias Oziolor *Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Liang Xue *Machine Learning and Computational Sciences, Pfizer Inc., Cambridge, MA, USA.
Dennis PelletierDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Darien CapunitanDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Emi KimotoPharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, USA.
Joel D FederspielDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Mark SheehanDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Seda AratDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Leah NewmanDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Gahyun LeeDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Jessie QianDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Steven KumpfDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Thomas A LanzDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Matthew MartinDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA. matthew.martin@pfizer.com.
Nagappan MathialaganDrug Safety Research and Development, Pfizer Inc., Groton, CT, USA. nagappan.mathialagan@pfizer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The distribution of expression of target genes can provide insights that advance understanding of target availability to aid therapeutic development purposes. The increase of use of biologics and novel modalities, combined with the opportunities of alternative to in vivo experimental methods in safety evaluation of new therapeutics. A detailed understanding of expression levels in target tissues is essential to selecting nonclinical species with the highest translational potential. We quantified the relative RNA and protein levels across more than 40 normal tissues and 5 nonclinical species several tissues in human. We identified patterns of cross-species and methodology relationships that can aid in the broader understanding of nonclinical experimental design. We observed expression profile similarity across tissues that favors species similarity, except for select nervous system and immune tissues. In exploring tissue specificity, we identified ubiquitous transcripts that encode tissue-specific proteins. We also assessed discordance between RNA and protein enrichment and revealed potential sites of synthesis and action of secreted proteins. These data and their relationships are foundational assets in toxicology study design and provide insights into biological regulation in drug discovery.

Indexed as

ProteomeTranscriptomeAnimalsHumansOrgan SpecificitySpecies SpecificityProteome

Identifiers

PMID42218200
PMCPMC13482810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.